Skip to main content
. 2023 Feb 28;15(5):1508. doi: 10.3390/cancers15051508

Figure 1.

Figure 1

Flow chart of the MM-EP1 study. The treatment algorithm for precision medicine was based on molecular abnormalities: t(11;14) chromosomal translocation therapeutically targeted by a BCL2 inhibitor; t(4;14) chromosomal translocation with fusion/FGFR3 rearrangement targeted by a FGFR3 inhibitor; and the BRAF V600E mutation targeted by a BRAF inhibitor. r/r MM: relapsed/refractory multiple myeloma, PS: performance status, MO: molecularly oriented, no-MO: no molecularly oriented.